Rocket Pharmaceuticals Inc (RCKT) concluded trading on Wednesday at a closing price of $5.40, with 6.55 million shares of worth about $35.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -67.80% during that period and on April 09, 2025 the price saw a gain of about 12.73%. Currently the company’s common shares owned by public are about 106.45M shares, out of which, 98.97M shares are available for trading.
Stock saw a price change of -14.29% in past 5 days and over the past one month there was a price change of -34.23%. Year-to-date (YTD), RCKT shares are showing a performance of -57.04% which decreased to -77.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.60 but also hit the highest price of $26.98 during that period. The average intraday trading volume for Rocket Pharmaceuticals Inc shares is 1.94 million. The stock is currently trading -25.29% below its 20-day simple moving average (SMA20), while that difference is down -38.85% for SMA50 and it goes to -64.21% lower than SMA200.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) currently have 106.45M outstanding shares and institutions hold larger chunk of about 101.06% of that.
The stock has a current market capitalization of $575.80M and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$2.73 in the same period. It has Quick Ratio of 9.30 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RCKT, volatility over the week remained 14.31% while standing at 9.01% over the month.
Analysts are in expectations that Rocket Pharmaceuticals Inc (RCKT) stock would likely to be making an EPS of -0.58 in the current quarter, while forecast for next quarter EPS is -0.59 and it is -1.61 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.82 which is -0.23 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.66 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 10.43% while it is estimated to increase by 34.78% in next year. EPS is likely to grow at an annualized rate of 73.89% for next 5-years, compared to annual growth of -11.60% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on March 12, 2025 offering an Outperform rating for the stock and assigned a target price of $50 to it. Coverage by Wedbush stated Rocket Pharmaceuticals Inc (RCKT) stock as an Outperform in their note to investors on December 30, 2024, suggesting a price target of $32 for the stock. Stock get a Neutral rating from Goldman on April 02, 2024.
